# Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma

> **NCT03422094** · PHASE1 · TERMINATED · sponsor: **Washington University School of Medicine** · enrollment: 3 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **BIOLOGICAL:** NeoVax
- **BIOLOGICAL:** Nivolumab
- **BIOLOGICAL:** Ipilimumab
- **PROCEDURE:** Research blood draw
- **PROCEDURE:** Leukapheresis for research

## Key facts

- **NCT ID:** NCT03422094
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-10-31
- **Primary completion:** 2020-04-26
- **Final completion:** 2020-12-31
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Manufacturer changed focus to cell therapy
- **Last updated:** 2021-10-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03422094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03422094, "Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03422094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*